TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1816842

Group type: EXPERIMENTAL
Intervention: Ni59‐65Cr26‐23Mo11‐9 mass per cent alloys
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ni74‐85Cr15‐13Mo5‐3 alloys
Number of subjects: 7
Study: 7040006

Group type: COMPARATOR
Intervention: Bare sclera operation technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sr 90 irradiation on the 1st, 7th and 14th postoperative day (maximum 3 X 1000 rad)
Number of subjects: 40
Study: 31351240

Group type: EXPERIMENTAL
Intervention: Stepped Care Intervention (SCI)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Enhanced Usual Care (eUCA)
Number of subjects: 907
Study: 29049336

Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Individual physical exercise
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Moderate level physical activity
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Increased exercising days
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 175
Study: 25688638

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day in 3 divided doses; n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched placebo capsules (n = 21)
Number of subjects: 40
Study: 25248764

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 μg
Number of subjects: 639

Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 639
Study: 21640495

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 540
Study: 19070462

Group type: EXPERIMENTAL
Intervention: Pharmacological trials
Number of subjects: 165

Group type: COMPARATOR
Intervention: Nonpharmacological trials
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Multicentered trials
Number of subjects: 165

Group type: COMPARATOR
Intervention: Single-site studies
Number of subjects: 165
Study: 17202811

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ondansetron (16 mg)
Number of subjects: 50
Study: 16225693

Group type: EXPERIMENTAL
Intervention: Acupuncture + physiotherapy
Number of subjects: 465

Group type: COMPARATOR
Intervention: TENS-placebo + physiotherapy
Number of subjects: 465
Study: 12544718

Group type: EXPERIMENTAL
Intervention: Combined therapy (calcium antagonist + beta-blocker)
Number of subjects: 0
Study: 10523945

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intense medical therapy
Number of subjects: 0
Study: 7568747

Group type: EXPERIMENTAL
Intervention: Floss Plus easy flosser
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hand-held floss
Number of subjects: 62
Study: 2177357

Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (2 monthly cycles of initial chemotherapy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (maintenance chemotherapy: 2 cycles or 4 cycles)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (initial chemotherapy)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cisplatin and vindesine (in responding patients)
Number of subjects: 81
Study: 7351151

Group type: EXPERIMENTAL
Intervention: Atropine sulphate (0.08 mg/kg) administered by inhalation, four times a day for seven days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoproterenol hydrochloride (2.5 mg) administered by inhalation, four times a day for seven days
Number of subjects: 24
Study: 31831561

Group type: EXPERIMENTAL
Intervention: Guadecitabine 30 mg/m2 s.c. once-daily for 5 days and carboplatin (G+C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Guadecitabine and carboplatin (G+C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment of choice (TC)
Number of subjects: 100
Study: 31146679

Group type: EXPERIMENTAL
Intervention: LVPEG-4 (1 L preparation + 1 L required additional fluid)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (2 L PEG + Asc)
Number of subjects: 120
Study: 27869451

Group type: EXPERIMENTAL
Intervention: Internet-delivered family-based cognitive-behavioral therapy (FB-CBT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clinic-based family-based cognitive-behavioral therapy (FB-CBT)
Number of subjects: 22
Study: 25567068

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Both AAD and RFA
Number of subjects: 294
Study: 24363933

Group type: EXPERIMENTAL
Intervention: Doxazosin added to current medication
Number of subjects: 611

Group type: COMPARATOR
Intervention: Current medications only (Control)
Number of subjects: 611
Study: 21157387

Group type: EXPERIMENTAL
Intervention: Isometric (ISO) conditioning contraction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concentric (CON) conditioning contraction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Eccentric (ECC) conditioning contraction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concentric‐eccentric (DYN) conditioning contraction
Number of subjects: 10
Study: 19520734

Group type: EXPERIMENTAL
Intervention: Locomotor training with therapist assistance
Number of subjects: 19

Group type: COMPARATOR
Intervention: Robotic‐assisted locomotor training
Number of subjects: 19
Study: 17712655

Group type: EXPERIMENTAL
Intervention: Removal of catheter and vaginal pack after 3 h
Number of subjects: 136

Group type: COMPARATOR
Intervention: Removal of catheter and vaginal pack after 24 h
Number of subjects: 136
Study: 15156431

Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-adherence support
Number of subjects: 0
Study: 11270011

Group type: COMPARATOR
Intervention: Single injection technique with 20 mL of ropivacaine 0.75%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple injection technique with 20 mL of ropivacaine 0.75%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple group
Number of subjects: 30
Study: 9727567

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) in combination with zalcitabine (ddC) (with or without ZDV) for 1 year
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) plus zalcitabine (ddC)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) treatment
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 169
Study: 8289855

Group type: EXPERIMENTAL
Intervention: Insurance coverage for ABMT
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Patients who underwent ABMT despite denial
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Patients who did not undergo ABMT
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Inconsistency in approval
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Predetermination process
Number of subjects: 533
Study: 2637530

Group type: EXPERIMENTAL
Intervention: Tablet fluoridation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complex preventive programmes
Number of subjects: 0
Study: 15780704

Group type: EXPERIMENTAL
Intervention: venlafaxine XR (225 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: paroxetine (30 mg/day)
Number of subjects: 20
Study: 31848757

Group type: EXPERIMENTAL
Intervention: Gasless BABA robotic thyroidectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional BABA robotic thyroidectomy (CO2 group)
Number of subjects: 28
Study: 31035478

Group type: EXPERIMENTAL
Intervention: 140 mL of concentrated beetroot juice (800 mg NO3‐)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (NO3‐‐depleted beetroot juice)
Number of subjects: 15
Study: 27593398

Group type: EXPERIMENTAL
Intervention: Syntometrine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 1200
Study: 25902705

Group type: EXPERIMENTAL
Intervention: Intensive anthelminthic treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard anthelminthic treatment
Number of subjects: 26
Study: 24195204

Group type: EXPERIMENTAL
Intervention: Bleeding and cupping therapy, applied locally with pricking and cupping once every two days for a total of 8 treatments.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pregabalin, 150mg orally, twice a day for a total of 16 days.
Number of subjects: 64
Study: 21242217

Group type: EXPERIMENTAL
Intervention: High exposure to cigarette advertisements
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Medium exposure to cigarette advertisements
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Low exposure to cigarette advertisements
Number of subjects: 2102
Study: 19091808

Group type: EXPERIMENTAL
Intervention: TREAT decision support system
Number of subjects: 161

Group type: COMPARATOR
Intervention: Clinical practice (first attending clinical physician's treatment)
Number of subjects: 161
Study: 16541783

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) LCT/MCT propofol
Number of subjects: 97

Group type: COMPARATOR
Intervention: 0.2 mg x kg(‐1) LCT propofol
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.4 mg x kg(‐1) LCT propofol
Number of subjects: 97

Group type: COMPARATOR
Intervention: 0.4 mg x kg(‐1) LCT/MCT propofol
Number of subjects: 97
Study: 15214587

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) vaginal gel, single-dose administration
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clindamycin vaginal cream, 1 daily administration for 7 days
Number of subjects: 110
Study: 10792202

Group type: EXPERIMENTAL
Intervention: Ceftazidime 40 mg kg‐1 8 hourly by bolus injection
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ceftazidime 4 mg kg‐1 h‐1 by constant infusion following a 12 mg kg‐1 priming dose
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ceftazidime (both interventions)
Number of subjects: 34
Study: 9186297

Group type: EXPERIMENTAL
Intervention: Tolrestat treatment for 4 weeks in 17 patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks in 17 patients
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Blood glucose control for 4 weeks in 7 patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal controls (7 subjects) treated with tolrestat for 4 weeks
Number of subjects: 79
Study: 8422517

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (any of the four regimens)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 164
Study: 3525423

Group type: EXPERIMENTAL
Intervention: Viminol R2 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29016867

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to M1 + PES to the back muscles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PES
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined tDCS + PES
Number of subjects: 20

Group type: COMPARATOR
Intervention: tDCS + sham PES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS + PES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS + sham PES
Number of subjects: 20
Study: 28416838

Group type: EXPERIMENTAL
Intervention: Robotic‐assisted percutaneous sacroiliac screw internal fixations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual operation guided by fluoroscopy
Number of subjects: 12
Study: 24734891

Group type: EXPERIMENTAL
Intervention: Insulin lispro (Lis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart (Asp)
Number of subjects: 0
Study: 24083403

Group type: EXPERIMENTAL
Intervention: Feeding assistance of moderate quality
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Stable weight over 3 months
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Weight loss over 3 months
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Mortality risk
Number of subjects: 256
Study: 21918241

Group type: COMPARATOR
Intervention: Pedometer 10,000 step goal
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pedometer step goal plus individualized motivational feedback
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pedometer step goal plus individualized motivational feedback and biweekly telephone feedback
Number of subjects: 81
Study: 18431498

Group type: EXPERIMENTAL
Intervention: ART with 3 cycles of interleukin-2 (IL-2) (4.5 million IU sc BID x 5 days every 8 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: ART without interleukin-2 (IL-2)
Number of subjects: 47
Study: 17242485

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 12571667

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (Novasoy, 50 mg daily of isoflavone equivalents)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 10627441

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 18
Study: 8884705

Group type: EXPERIMENTAL
Intervention: Thigh-high antiembolic compression stockings (TED hose)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Antiembolic stockings and pneumatic compression stockings
Number of subjects: 117
Study: 1575787

Group type: EXPERIMENTAL
Intervention: Monthly telephone contact by lay personnel
Number of subjects: 40
Study: 3855339

Group type: EXPERIMENTAL
Intervention: Nd YAG laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 25
Study: 31285208

Group type: EXPERIMENTAL
Intervention: Higher empathy scores (middle tertile)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Higher empathy scores (highest tertile)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Lowest empathy scores (control group)
Number of subjects: 867
Study: 27997877

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (0.02 μg kg‐1 min‐1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 27129091

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony capsule (TGPC) combined with corticosteroids
Number of subjects: 81

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 81
Study: 24674816

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dorsal manipulation
Number of subjects: 30
Study: 22349843

Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation (Rehacop)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 93
Study: 20509477

Group type: EXPERIMENTAL
Intervention: Oxum (super oxidised water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Betadine
Number of subjects: 30
Study: 17955771

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albumin (n = 30)
Number of subjects: 60
Study: 15886538

Group type: EXPERIMENTAL
Intervention: Prehypertension
Number of subjects: 53163

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 53163

Group type: COMPARATOR
Intervention: Normal blood pressure
Number of subjects: 53163
Study: 17176125

Group type: EXPERIMENTAL
Intervention: dTpa (Boostrix™)
Number of subjects: 4100
Study: 10553817

Group type: EXPERIMENTAL
Intervention: Tight control of blood glucose with a standardized IV insulin infusion (Group TC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No control of blood glucose (Group NC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups experienced significant increases in blood glucose levels during hypothermic cardiopulmonary bypass
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups experienced similar significant increases in postoperative serum levels of CK‐BB and S‐100 protein
Number of subjects: 20
Study: 8705091

Group type: EXPERIMENTAL
Intervention: Policosanol 1 mg twice daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1803333

Group type: COMPARATOR
Intervention: Zinc oxide‐eugenol (Cavitec)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Life)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Direct pulp capping agents (Life and Dycal)
Number of subjects: 21
Study: 6601648

Group type: EXPERIMENTAL
Intervention: Rifaprim (RPM) - 450 mg RIF + 120 mg TMP twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rifaprim (RPM) - 600 mg RIF + 160 mg TMP at bedtime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rifaprim (RPM) - 800 mg SMZ + 160 mg TMP twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-trimoxazole (CO-T) - 800 mg SMZ + 160 mg TMP twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-trimoxazole (CO-T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rifaprim (RPM)
Number of subjects: 60
Study: 30095742

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at 2100 m (FiO2: 0.18)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at 1400 m (FiO2: 0.195)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia at 580 m (FiO2: 0.21)
Number of subjects: 8
Study: 29941003

Group type: EXPERIMENTAL
Intervention: Anthroposophic therapeutic speech (ATS), 11 sessions
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 63
Study: 27216134

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily for 48 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Atripla
Number of subjects: 57
Study: 25247995

Group type: EXPERIMENTAL
Intervention: IPTp-MQ (15 mg/kg)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1071
Study: 22573627

Group type: EXPERIMENTAL
Intervention: Lubiprostone (Amitiza) titrated up to 48 μg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lubiprostone
Number of subjects: 54
Study: 20332739

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg-1 + ketamine 0.5 mg.kg-1
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol 0.5 mg.kg-1 + ketamine 0.25 mg.kg-1
Number of subjects: 72
Study: 17275763

Group type: COMPARATOR
Intervention: AV junction ablation
Number of subjects: 670

Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 670
Study: 15632335

Group type: EXPERIMENTAL
Intervention: Atkins diet (carbohydrate restriction)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Zone diet (macronutrient balance)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Weight Watchers diet (calorie restriction)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ornish diet (fat restriction)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 160
Study: 12077156

Group type: EXPERIMENTAL
Intervention: Cefpodoxime 400 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefixime 400 mg
Number of subjects: 6
Study: 10401916

Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Compressed air inhalation
Number of subjects: 13
Study: 7593425

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 57
Study: 30476202

Group type: EXPERIMENTAL
Intervention: Nighttime sleep (measured in minutes)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sedentary activity (measured in minutes)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cross-lagged effects of sleep on sedentary behavior
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cross-lagged effects of sedentary behavior on sleep
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Within-person standardized cross-lagged effects
Number of subjects: 195
Study: 27991807

Group type: EXPERIMENTAL
Intervention: Perceptual learning through a 3-day training session using an orientation discrimination task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual learning for older adults.
Number of subjects: 0
Study: 25688819

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 159

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 159
Study: 23323897

Group type: EXPERIMENTAL
Intervention: 48-week ART
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 12-week ART
Number of subjects: 366

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 366
Study: 22464834

Group type: EXPERIMENTAL
Intervention: Question Prompt Lists (QPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no QPL)
Number of subjects: 0
Study: 19111075

Group type: EXPERIMENTAL
Intervention: TENS treatment (5 times per week for 4 weeks, 60 Hz, 100 microS, 25 mA, 20 minutes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 24
Study: 15975277

Group type: EXPERIMENTAL
Intervention: DC vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (chemotherapy only)
Number of subjects: 30
Study: 12464163

Group type: EXPERIMENTAL
Intervention: Fish-free diet (diet 1; n = 19)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet including fish frozen for more than 48 hours (diet 2; n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet with fresh fish (diet 3; n = 12)
Number of subjects: 28
Study: 10485548

Group type: EXPERIMENTAL
Intervention: Localized wedge-shaped defects of RNFL in the hemorrhage group (NTG and POAG)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Localized wedge-shaped defects of RNFL in NTG and POAG
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Location of disc hemorrhages
Number of subjects: 83
Study: 8912771

Group type: EXPERIMENTAL
Intervention: Asthmatic subjects (both atopic and nonatopic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (atopic and nonatopic)
Number of subjects: 0